La Jolla Pharmaceutical Company (LJPC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
43
About the Report
About the Report
Summary
La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company's major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its clinical-stage investigational product includes LJPC-401, a formulation of synthetic human hepcidin intended for the treatment of iron overload, such as hereditary hemochromatosis, sickle cell disease, beta thalassemia and myelodysplastic syndrome. The company distributes its products through a network of specialty distributors to hospitals across the US. La Jolla is headquartered in San Diego, California, the US.
La Jolla Pharmaceutical Company (LJPC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
La Jolla Pharmaceutical Company, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
Licensing Agreements 15
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15
IURTC Enters into Licensing Agreement with La Jolla Pharma 16
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17
La Jolla Pharma Enters into Licensing Agreement with George Washington University 18
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19
Equity Offering 20
La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For USD 6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For USD 3.3 Million 29
La Jolla Pharmaceutical Company-Key Competitors 30
La Jolla Pharmaceutical Company-Key Employees 31
La Jolla Pharmaceutical Company-Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Oct 24, 2018: La Jolla Pharmaceutical Company Reports Financial Results for the Three and Nine Months Ended September 30, 2018 33
Aug 08, 2018: La Jolla Pharmaceutical company announces financial results for the three and six months ended June 30, 2018 and recent corporate progress 34
May 10, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress 35
Feb 22, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress 37
Oct 26, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 38
Jul 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 39
Apr 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 40
Feb 23, 2017: La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress 41
Product News 42
09/13/2017: Researchers Develop New Strategy to Target KRAS Mutant Cancer 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Figure
List of Figures
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15
IURTC Enters into Licensing Agreement with La Jolla Pharma 16
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17
La Jolla Pharma Enters into Licensing Agreement with George Washington University 18
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19
La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For USD 6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For USD 3.3 Million 29
La Jolla Pharmaceutical Company, Key Competitors 30
La Jolla Pharmaceutical Company, Key Employees 31
La Jolla Pharmaceutical Company, Subsidiaries 32
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.